September 2016 Newsletter
IASLC To Offer CME Credits for Select JTO Articles Starting This Fall
The International Association for the Study of Lung Cancer is delighted to announce the initiation of a program for awarding continuing medical education (CME) credits for JTO manuscript review. For specific types of articles (as selected by the Editor-in-Chief), reviewers may be eligible to earn up to 15 AMA PRA Category 1 Credits™ annually. CME accreditation will begin to be awarded this fall following the release of new Commendation Criteria by the Accreditation Council for Continuing Medical Education (ACCME).
IASLC's 7th LALCA Conference a Great Success
The IASLC 7th Latin America Conference on Lung Cancer (LALCA) was held August 25-27, 2016. Attended by nearly 500 delegates from over 40 different countries, the meeting provided a format for fruitful exchange and drew attention to the Latin American region, where lung cancer is one of the leading causes of death.
This year's LALCA also included a rigorous and expansive scientific program. Over 120 abstracts were accepted into the conference, representing the work of delegates from over 20 different countries. Additionally, the IASLC awarded five travel awards to young Latin American researchers, designed to help defray the costs of attending LALCA.
The IASLC would like to thank all attendees, presenters, and sponsors for helping to make this year's IASLC LALCA possible! We are already eagerly anticipating the next LALCA conference, which is set to take place in Cordoba, Argentina on August 16-19, 2018!
Read the Third Issue of the IASLC Lung Cancer News
The third issue of the IASLC Lung Cancer News is now available online. This issue features:
To read the publication online simply follow this link, or download a PDF of the publication. The IASLC invites readers to submit article ideas, in addition to new content for future “Names and News” columns, to email@example.com. All submissions are subject to review and approval by the magazine’s editor, and selection for publication is not guaranteed.
Mesothelioma Awareness Day is September 26, 2016
Malignant mesothelioma is a tumor of the lining of the lung and chest cavity or lining(s) of the abdomen, often related to exposure to carcinogenic mineral fibers such as asbestos and erionite.Genetics also influences the risk of developing mesothelioma. For instance, among crocidolite-asbestos miners who worked for over 10 years in South African asbestos mines, 4.6% developed mesothelioma after a period of about 30-40 years, suggesting that some of them were more susceptible to asbestos carcinogenesis.
Established by Meso Foundation volunteers in 2004, Mesothelioma Awareness Day is a powerful force in raising awareness, generating funding, and ultimately driving progress in the treatment of this particular type of cancer.
There are many ways to participate in this national awareness day. The Mesothelioma Applied Research Foundation has compiled a list of various strategies that are effective and easy to execute. Those interested can also participate by using social media to raise awareness. The specific hashtags to use on the awareness day are: #MesoAwarenessDay and #ENDMeso.
Regional Organizing Committee (ROC) Application for WCLC 2019 (Europe)
Applications are now being accepted for parties interested in forming a Regional Organizing Committee (ROC) for the IASLC's 20th World Conference on Lung Cancer (WCLC), which will take place in Barcelona, Spain in November 2019. The ROC will be composed of 15-20 IASLC members, and will provide regional leadership to help develop the WCLC's scientific program, social events, and overall logistical plan.
Other responsibilities of the ROC include: planning onsite workshops, arranging travel grants and awards, and assisting with press releases and marketing efforts. For a full description of the ROC's role and a link to the application, please visit our website or download the application.
Academic, Career, and Funding Opportunities
As a service to our members, we post opportunities related to lung cancer and other thoracic malignancies on our website.
This now includes academic career opportunities. Click here to review post-doctoral and other career opportunities submitted to IASLC. If you have an academic career opportunity, please email it to firstname.lastname@example.org.
We also post opportunities when we receive information from grantors. We currently have five funding opportunities:
These opportunities are available to applicants from all countries. Click here to learn more.
Social Media Corner: Twitter and Mesothelioma - The Good, The Bad, and The Ugly
By Alicia Hart, MD Candidate at UC Davis
As a medical student using Twitter to conduct patient-centered outcomes research, I came to view it as a magnificent highway connecting patients to caregivers to HCPs. Hence, when my husband was diagnosed with mesothelioma, I took to Twitter in search of a larger community.
Amidst lots of online support, I also found asbestos lawyers looking for clients. They tweet links to sites maintained by their respective firms where they disseminate legal advice alongside medical information. Their tweets flood the mesothelioma hashtag making it more difficult for those affected by the disease to connect and share information. Additionally, after sharing my husband’s diagnosis, I promptly received messages from asbestos firms offering condolences and asking if I needed help. I did, but from caregivers and HCPs, not lawyers!
In sharing my experience, I hope to educate the IASLC community on how some legal firms can impede the use of social media amongst this patient population. Perhaps the time has come to issue a code of practice, which must be adhered to when engaging with patients through social media.
Help raise awareness during Mesothelioma Awareness Day on Sept. 26 with the hashtags: #MesoAwarenessDay and #ENDMeso.
September 2016: The IASLC and the Journal of Thoracic Oncology (JTO) are pleased to present the Editor's Choice each month to highlight certain articles of interest. The selected articles will be made available to the public for a limited time upon printing. The articles below from the September issue of the JTO are free for three months. Please share with your colleagues around the globe!
Alex A. Adjei, MD, PhD
The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of Non-Small Cell Lung Cancer in the Forthcoming (8th) Edition of the TNM Classification of Lung Cancer
The IASLC Lung Cancer Staging Committee has been working on the 8th edition of the TNM classification for lung cancer. Manuscripts describing the T, N, and M descriptors as well as the stage groupings for NSCLC and the clinical and pathologic staging of small cell lung cancer have already been published in this journal. In this issue, Detterbeck and colleagues describe the methodology and validation used for stage classification.
The early evaluations of MET inhibitors in NSCLC were disappointing, with failed phase III trials with tivantinib and onartuzumab, among others. MET exon 14 alterations at RNA splice acceptor or donor sites have been recently described as a distinct mechanism of MET activation, leading to MET exon 14 skipping. Tumors harboring this mutation have been found to be sensitive to small molecule MET inhibitors. In this volume, there are two manuscripts describing exon 14 skipping mutations. In the first manuscript, Shrock et al describe the characteristics of the exon 14 skipping mutation in 298 lung cancer patients.
In the second manuscript, Liu et al describe MET exon 14 mutations in Chinese lung cancer patients. These two manuscripts are accompanied by an excellent editorial by Dr. Ravi Salgia.
Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping
Finally, the clinical course and management of a number of malignancies such as breast cancer in pregnancy have been well-studied. Because lung cancer tends to be a disease of the elderly, there is little data on lung cancer in pregnancy. Thus, the report from Dr. Dagogo-Jack and her colleagues describing the molecular features of NSCLC diagnosed in pregnancy is very valuable.
The following articles were selected from the JTO by the IASLC Communications Committee to be promoted to the media and the public with press releases that were released at the time of online publication (Published Ahead of Print).
To read more IASLC Press Releases, please visit IASLC Research Articles. These press releases are also announced via social media, so please follow IASLC on Twitter, LinkedIn, and Facebook to stay up to date on the latest scientific topics.
Leptomeningeal Metastases Are More Common in NSCLC Patients Harboring EGFR Mutations and Respond Positively to TKI Therapy
Leptomeningeal metastases (LM), a devastating complication and predictor of poor survival in lung cancer patients, was found to be more prevalent in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations.
Analysis of a large non-small cell lung cancer (NSCLC) patient cohort with stage IV M1a disease identified lymph node staging as having clinical significance and an impact on prognosis.
There are two ways you can access the JTO:
1. Login via the IASLC Membership Portal with your username and password. Once signed in, select “JTO Member Access” from the left hand menu and click “Journal of Thoracic Oncology.” Here you will have access to the JTO articles free for members.
2. To get selected features on the Elsevier website like Publish-Ahead-of-Print (PAP) alerts, individual search history, or saved articles, you can also set up a custom account on the new www.jto.org site. If you have not already done so, click here to set up an account by following the steps below:
a. Click "Create Account," then complete the "Register a New Account" form, and click "Register."
b. On the "Claim Online Access" page, select “I receive my subscription through a society membership”
*Please note that you will need to enter your IASLC member ID number on the first visit in order to claim your subscriber access. You will then enter a new password which will suffice for future visits to the JTO website.
Should you have any questions regarding your access to the online JTO, please contact our Membership team at: email@example.com.
Member Discount for IASLC 17th World Conference on Lung Cancer
To find your Member ID in your IASLC account:
1. Login. Enter your Username and Password. If you have forgotten your password, you can always reset it with the “Forgot Password” button on your screen. Once signed into your account, click “My Details” on the right side of your screen. You will then see your Member ID appear towards the top of your screen.
2. You will also find your Member ID in any past renewal email notices, invoices, or on your Member ID Card from IASLC. However, please feel free to email firstname.lastname@example.org and we will be happy to provide your Member ID for you right away.
Member Account Information
Free Membership for Patients/Survivors
The IASLC has a free membership option for patients and survivors of any thoracic malignancy. All patients/survivors with a diagnosis of lung cancer, mesothelioma, or other thoracic cancer qualify for this free membership. Patients and survivors can renew this non-voting membership annually. Except for voting, the patient/survivor membership includes all Allied Health Professional member benefits, and includes online access to the JTO, member meeting discounts, eligibility to apply for travel awards, and eligibility to serve on Committees. Register as Patient/Survivor.
Update on Lung Cancer Awareness Month Strategy Project (LCAM2016)
The August call of the Lung Cancer Awareness Month (LCAM) consortium was conducted on August 31, 2016. A particular welcome was extended to Stefania Vallone, President of Lung Cancer Europe (LUCE). While the project was started as a US “pilot" initiative, we hope to expand internationally and appreciate the interest and activities of LUCE.
A "Memorandum of Understanding" has been distributed to be signed by all participants. It outlines the goals of the harmonization strategy and asks participants to commit to the strategy's promotional tactics in order to maximize the campaign's impact.
Plans for promoting the campaign are also well-underway, with designs on promoting the campaign through paid, digital, and social media. Additionally, Dr. Hirsch revealed that several sponsors are interested in potentially supporting the project, and the IASLC is following up with them. Dusty Donaldson, representing LungCAN, will take the lead in organizing a National Press Club Media Breakfast in Washington, DC. She has asked for the participation from as many groups as possible. A face-to-face meeting will take place in Chicago prior to the IASLC's Chicago Multidisciplinary Symposium on September 22. For more information, or to join the harmonized strategy for November's Lung Cancer Awareness Month, please contact Kristin Richeimer at Kristin.email@example.com.
Become a Member
Join the only international association solely dedicated to lung cancer research and treatment.
WCLC Virtual Library
February 20 - 23 2019Santa Monica, California
April 3 - 5 2019New York, New York
April 10 - 13 2019Geneva, Switzerland